BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15723837)

  • 1. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
    Phelps M; Phillips A; Darley M; Blaydes JP
    J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.
    Phillips A; Blaydes JP
    Oncogene; 2008 Mar; 27(11):1645-9. PubMed ID: 17828301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
    Roth J; Dobbelstein M; Freedman DA; Shenk T; Levine AJ
    EMBO J; 1998 Jan; 17(2):554-64. PubMed ID: 9430646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation.
    Migliorini D; Danovi D; Colombo E; Carbone R; Pelicci PG; Marine JC
    J Biol Chem; 2002 Mar; 277(9):7318-23. PubMed ID: 11744695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
    Tao W; Levine AJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.
    Jackson MW; Patt LE; LaRusch GA; Donner DB; Stark GR; Mayo LD
    J Biol Chem; 2006 Jun; 281(24):16814-20. PubMed ID: 16621805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis.
    Phillips A; Darley M; Blaydes JP
    Oncogene; 2006 Jul; 25(30):4183-93. PubMed ID: 16501602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
    AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
    Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
    Joseph TW; Zaika A; Moll UM
    FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression.
    Bárdos JI; Chau NM; Ashcroft M
    Mol Cell Biol; 2004 Apr; 24(7):2905-14. PubMed ID: 15024078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.
    Laín S; Midgley C; Sparks A; Lane EB; Lane DP
    Exp Cell Res; 1999 May; 248(2):457-72. PubMed ID: 10222137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
    Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
    Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
    Heminger K; Markey M; Mpagi M; Berberich SJ
    Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
    Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG
    J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.